Cogent Biosciences (NASDAQ:COGT) Bolsa

Cogent Biosciences

Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.

Cogent Biosciences Inc

GoodRx Holdings Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDRX#NASDAQ">GDRX</a>) reported fourth-quarter revenue of $198.6 million, up slightly by 1% year over year, missing the management guidance of around $200 million and <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $199.75 million</a>.
Fiscal year sales of $792.3 million came in below the guidance of <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b41800510/goodrx-reports-third-quarter-2024-results" rel="noreferrer noopener">around $794 million</a>.
The company reported adjusted EPS of 9 cents, up from 8 cents a year ago, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b44000935/goodrx-reports-fourth-quarter-and-full-year-2024-results" rel="noreferrer noopener">missing the consensus of 10 cents</a>.
Q4 prescription transactions revenue increased 0.8% to&nbsp;$144.9 million. 2024 prescription transactions revenue increased 5% to $577.5 million, driven by an organic 7% increase in Monthly Active Consumers, including the expansion of an integrated savings program.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/12/42349122/how-much-did-americans-overspend-on-weight-loss-medications-in-2024-goodrx-reveals" rel="noreferrer noopener">How Much Did Americans Overspend On Weight Loss Medications in 2024? GoodRx Reveals</a>
GoodRx exited the fourth quarter of 2024 with over 7 million prescription-related consumers using GoodRx across prescription transactions and subscription offerings. Monthly active consumers were 6.6 million, with subscription plans of 684k.
The 2024 subscription revenue decreased by 8% to $86.5 million, primarily driven by a decrease in subscription plans due to the sunset of the partnership subscription program, Kroger Savings Club. In Q4, subscription revenue fell 10.7% to $20.68 million.
Q4 Pharma manufacturer solutions revenue jumped from $24.4 million to $28.1 million. 2024 Pharma manufacturer solutions revenue increased 26% to $107.2 million, primarily driven by organic growth as the company expands market penetration with pharma manufacturers and other customers.
Adjusted EBITDA reached $67.08 million in Q4 and $260.2 million in 2024.
Guidance: The prescription savings platform expects a fiscal year 2025 revenue outlook of $810 million—$840 million, up 2%—6% versus the consensus of $825.57 million, with adjusted EBITDA of $270 million—$286 million.
GoodRx forecasts first-quarter 2025 revenue of $201 million—$205 million, up 2%-4%, versus consensus of $202.53 million, with an adjusted EBITDA margin of about 33%.
Price Action: GDRX stock is up 4.6% at $5.12 at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/44006958/bath-body-works-posts-4-sales-decline-in-q4-stock-plunges" target="_blank" rel="noreferrer noopener">Bath &amp; Body Works&#8217; Stock Slips As Soft Outlook Overshadows Q4 Earnings Beat: Details</a></li>
</ul>
Photo: Shutterstock

Earnings

News

Guidance

Health Care

Movers

Trading Ideas

General

GDRX

GoodRx Reports Mixed Q4: Pharma Strength Amid Subscription Decline, Sluggish Prescription Sales

DA Davidson analyst Linda Bolton Weiser maintains Usana Health Sciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USNA#NYSE">USNA</a>) with a Neutral and lowers the price target from $38 to $36.

Price Target

Analyst Ratings

USNA

DA Davidson Maintains Neutral on Usana Health Sciences, Lowers Price Target to $36

JP Morgan analyst Pinjalim Bora maintained an Underweight rating on C3.ai, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AI#NYSE">AI</a>) with a <a target="_blank" href="https://www.benzinga.com/quote/AI/analyst-ratings" rel="noreferrer noopener">price target of $27, down from $28</a>.
C3.ai reported a <a target="_blank" href="https://www.benzinga.com/news/earnings/25/02/43992114/c3ai-q3-earnings-highlights-revenue-beat-eps-beat-significant-milestones-achieved" rel="noreferrer noopener">third-quarter revenue</a> of $98.8 million, up 26%. The revenue total beat a Street consensus estimate of $98.1 million.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/25/02/44008324/echostar-q4-3-97-billion-revenue-narrows-pay-tv-subscriber-losses-focuses-on-high-quality-users-wireless-growth" rel="noreferrer noopener">EchoStar Q4: $3.97 Billion Revenue, Narrows Pay-TV Subscriber Losses, Focuses On High-Quality Users, Wireless Growth</a>
The company had an adjusted net loss of 12 cents per share, which beat a street consensus estimate of 25 cents per share.
C3.ai expects fourth-quarter revenue of $103.6 million-$113.6 million, versus the consensus estimate of $108.6 million.
Bora updated his AI model to include the third quarter of fiscal 2025 results. The price target is based on ~7 times EV/calendar 2026E revenue (unchanged) relative to infrastructure software companies growing FTM revenue over 20%, trading at ~10x EV/calendar 2026E revenue.
The lower price target reflects subpar core growth, adjusted for demo licenses.
The analyst noted that AI should trade at a significant discount to this group as growth is similar but at a much smaller scale for AI. Also, AI is extremely unprofitable compared to the comps.
While AI will likely grow FTM revenue at a comparable growth level (23% versus 24% for the comps&#8217; median), AI is 80% smaller than the median scale of the comp group.
Additionally, AI will likely have (14%) FTM free cash flow margin driving a growth plus margin profile of 9%, versus comps at +22% Unlevered Free Cash Flow (UFCF) margin driving a growth plus margin of +46%. Furthermore, the calendar 2025 adjusted operating margin for AI will likely be (24%) versus comps at +15%.
Price Action: AI stock is down 6.24% at $25.05 at last check Thursday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/25/02/44007299/warner-bros-q4-earnings" target="_blank" rel="noreferrer noopener">Warner Bros Q4 Earnings: Studios Revenues Grow 16%, Max Subscribers Surge, Eyes 150 Million Subscribers By 2026</a></li>
</ul>
Photo via Shutterstock

Reiteration

Tech

C3.ai Sees Stronger Revenue But Analyst Concerned Over Profitability And Scale

Joby Aviation, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JOBY#NYSE">JOBY</a>) shares are trading higher on Thursday. On Wednesday, the company reported fourth-quarter losses of 34 cents per share. This missed the analyst consensus estimate for a loss of 20 cents and revenue of $55,000, beating the <a href="https://www.benzinga.com/news/earnings/25/02/43993466/joby-aviation-stock-climbs-after-q4-results-heres-why" target="_blank" rel="noreferrer noopener">analyst consensus estimate of $45,800</a>.
JPMorgan analyst Bill Peterson cut the price forecast to $5.00 from $6.00 while <a href="https://www.benzinga.com/quote/JOBY/analyst-ratings" target="_blank" rel="noreferrer noopener">maintaining an Underweight rating</a>.
The analyst&#8217;s bearish stance reflects the expected higher cash burn outlook and delays in aircraft deliveries.
Notably, the analyst writes that cash burn will rise as Joby expands its manufacturing capabilities to support increased production rates for parts.
Also, Peterson says that further delays are expected for the commercial launch in Dubai, depending on the progress of GCAA verification and infrastructure development in the UAE.
A similar situation may unfold in the U.S. TIA flight testing will begin within the next year. This could push a small-scale commercial launch to the second half of 2026, adds the analyst.
Meanwhile, the analyst says that the defense sector remains a key market opportunity, with spending expected to rise further in 2025/2026.
While it is still too early to determine the full scope of the defense market opportunity, its potential will likely depend on specific applications, such as logistics versus combat operations, adds the analyst.
Given the capital-intensive nature of the business, the company will likely pursue additional funding opportunities. Spending is anticipated to accelerate further as it moves toward commercialization, adds the analyst.
Investors can gain exposure to Joby through two exchange-traded funds, or ETFs: 
<ul>
<li>WisdomTree Trust WisdomTree Battery Value Chain and Innovation Fund (BATS:<a class="ticker" href="https://www.benzinga.com/stock/WBAT#BATS">WBAT</a>)</li>
<li>ARK Space Exploration &amp; Innovation ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKX#BATS">ARKX</a>).</li>
</ul>
Price Action: Joby Aviation shares are up 4.64% at $7.01 at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/etfs/specialty-etfs/25/02/43946240/rocket-lab-kratos-archer-aviation-and-more-earnings-this-week-could-have-a-big-impact-on-cathie-woods-ark-etfs" target="_blank" rel="noreferrer noopener">Rocket Lab, Kratos, Archer Aviation And More Earnings This Week Could Have A Big Impact On Cathie Wood&#8217;s Ark ETFs</a></li>
</ul>
Image: Courtesy of Joby Aviation, Inc.

Equities

Mid Cap

ARKX

JOBY

WBAT

Joby Aviation Posts Mixed Q4 Results, Beware Of Higher Cash Burn And Aircraft Delivery Delays: Analyst

Macquarie analyst Paul Golding maintains Planet Fitness (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLNT#NYSE">PLNT</a>) with a Neutral and lowers the price target from $99 to $95.

PLNT

Macquarie Maintains Neutral on Planet Fitness, Lowers Price Target to $95

ACMR, ALAB, AMAT, AMBA, AMD, AMKR, AOSL, ARM, ARQQ, ASML, ASX, ATO, CAMT, CRDO, ENTG, FORM, HIMX, ICHR, INTC, KLAC, KLIC, LAES, LRCX, MKSI, MTSI, MU, MXL, NN, NVDA, NVMI, NVTS, ONDS, ONTO, QUIK, RGTI, RMBS, SITM, SKYT, SMH, SMTC, SOXX, STM, TSEM, TSM, UCTT, VUZI, WOLF

WIIM

ALAB

AMAT

AMBA

AMCR

AMKR

AOSL

ARQQ

ASML

CAMT

CRDO

ENTG

FORM

HIMX

ICHR

KLAC

KLIC

LRCX

MKSI

MTSI

NVDA

NVMI

NVTS

ONDS

ONTO

QUIK

RGTI

RMBS

SITM

SKYT

SMTC

iShares PHLX SOX Semiconductor Sector Index Fund

SOXX

TSEM

UCTT

VUZI

Shares of semiconductor companies are trading lower in sympathy with Nvidia, which reversed amid a possible selloff after reporting Q4 financial results.

Project awards represent approximately $1.25 billion in customer-focused investments for FirstEnergy Transmission and $46 million for other FirstEnergy subsidiaries
AKRON, Ohio, Feb. 27, 2025 /PRNewswire/ -- FirstEnergy Transmission LLC (FET), jointly owned by FirstEnergy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FE#NYSE">FE</a>) and Brookfield Super-Core Infrastructure Partners, has been awarded multiple transmission projects by grid operator PJM Interconnection&nbsp;that are designed to strengthen the electric grid and support regional economic growth. The awards include projects that FET will develop through the Valley Link Transmission Company LLC joint venture with Dominion Energy and American Electric Power Company, as well as projects that FET will develop individually within its service territory.
In total, FET will invest approximately $1.25 billion in the approved customer-focused transmission projects. In addition,&nbsp;FirstEnergy's Potomac Edison, JCP&amp;L and Keystone Appalachian Transmission Company (KATCo)&nbsp;subsidiaries&nbsp;will invest $46 million upgrading equipment at substations and reconfiguring transmission lines in Maryland, New Jersey and Pennsylvania.
The projects were proposed through PJM's 2024 Regional Transmission Expansion Plan (RTEP) open window process and were approved Feb. 26 by the PJM Board of Managers. PJM is the regional transmission organization that coordinates the transportation of wholesale electricity across the 13-state region that includes FirstEnergy's service territory.

Contracts

FirstEnergy Awarded Projects By PJM Interconnection To Enhance Reliability And Address Rising Customer Demand; $1.25B Grid Enhancement Projects, $46M Upgrades For Subsidiaries

Scotiabank analyst Allan Verkhovski maintains ZoomInfo Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZI#NASDAQ">ZI</a>) with a Sector Perform and raises the price target from $10.3 to $11.

Scotiabank Maintains Sector Perform on ZoomInfo Technologies, Raises Price Target to $11

Joe Rogan, a longtime admirer of Elon Musk, recently pushed back against the billionaire's claims about Social Security fraud, calling them misleading. On a recent <a href="https://www.youtube.com/watch?v=hRH02-Z8F34">episode</a> of &#8220;The Joe Rogan Experience,&#8221; he and guest Mike Baker discussed Musk's assertion that millions of dead Americans—some supposedly 150 years old—are receiving Social Security benefits.
<h2 class="wp-block-heading">Misinterpretation or Fraud?</h2>
Musk first made the claim during a meeting in the Oval Office earlier this month, stating he had found &#8220;crazy things&#8221; in the Social Security system, including people marked as alive despite being impossibly old. He later doubled down on social media, <a href="https://x.com/elonmusk/status/1891350795452654076">posting</a> screenshots of data that he said showed widespread fraud.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">According to the Social Security database, these are the numbers of people in each age bucket with the death field set to FALSE! Maybe Twilight is real and there are a lot of vampires collecting Social Security &#x1f923;&#x1f923; <a href="https://t.co/ltb06VX98Z">pic.twitter.com/ltb06VX98Z</a>
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1891350795452654076?ref_src=twsrc%5Etfw">February 17, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Don't Miss:
<ul>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
<li>The secret weapon in billionaire investor portfolios that you almost certainly don't own yet. <a href="https://www.benzinga.com/money/masterworks">See which asset class has outpaced the S&amp;P 500 (1995-2024) – and with near-zero correlation.</a></li>
</ul>
President Donald Trump repeated Musk's numbers a few days laterr during a Mar-a-Lago press conference, raising concerns about potential fraud in the system. &#8220;Now, the big thing is, how many of these people got paid?&#8221; Trump asked, suggesting that if the numbers were true, it would be &#8220;a massive fraud.&#8221;
However, Social Security experts quickly dismissed the claims. Kathleen Romig from the Center on Budget and Policy Priorities pointed out to ABC News that the numbers were exaggerated, stating, &#8220;So, when they&#8217;re throwing around numbers like tens of millions of dead people are getting Social Security, well, they&#8217;re throwing around numbers like tens of millions of dead people are getting Social Security, well, there&#8217;s only 67 million total. What are they talking about? Half the people are actually dead? The numbers are so ridiculous. It&#8217;s not true.&#8221;
Trending: If there was a new fund backed by Jeff Bezos offering a <a href="https://www.benzinga.com/money/arrived-private-credit-fund">7-9% target yield with monthly dividends would you invest in it</a>?
<h2 class="wp-block-heading">Rogan&#8217;s Take</h2>
Rogan, who had Elon Musk five times on his podcast and once <a href="https://www.benzinga.com/news/24/05/38978082/joe-rogan-says-elon-musk-is-his-favorite-billionaire-i-will-buy-teslas-as-long-as-they-sell-them-jus">called him his &#8220;favorite billionaire,&#8221;</a> took a skeptical stance on this claim, bringing up insights from experts who understand COBOL, the outdated programming language still used in government systems. He read from a <a href="https://x.com/House0fCarter/status/1891633822103380003">post</a> explaining that Social Security databases often misinterpret missing data. If a person's birth or death date is missing, the system defaults to the year 1875, making it appear as though someone is 150 years old.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Joe Rogan thinks Elon Musk should stop lying about Social Security <a href="https://t.co/f6weGjtcQ9">pic.twitter.com/f6weGjtcQ9</a>
&mdash; Social Security Works (@SSWorks) <a href="https://twitter.com/SSWorks/status/1892949380593819712?ref_src=twsrc%5Etfw">February 21, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
&#8220;This isn&#8217;t a vampire conspiracy,&#8221; Rogan said, mocking the idea that hundreds of 300-year-old people are collecting Social Security checks. &#8220;The people that actually understand it are saying that&#8217;s not really the case.&#8221;
See Also: <a href="https://www.benzinga.com/money/elon-musk-told-the-u-n-if-they-could-show-a-plan-for-ending-world-hunger-hed-donate-6-billion-i-will-sell-tesla-stock-right-now-and-do-it">Elon Musk Told The U.N. If They Could Show A Plan For Ending World Hunger He'd Donate $6 Billion – ‘I Will Sell Tesla Stock Right Now And Do It'</a>
Baker added that Musk's claim was an overreaction to bad data rather than evidence of fraud. &#8220;It doesn&#8217;t even necessarily mean that all these people are receiving checks,&#8221; he said. &#8220;They&#8217;re just listed on the files, and it doesn&#8217;t mean money&#8217;s going out to them.&#8221;
&#8220;From a messaging perspective, does Elon need to screenshot that and then send it out as a tweet and then suddenly you&#8217;ve got a couple million people going, &#8216;Oh my God, we&#8217;re paying dead people,'&#8221; Baker asked.
<h2 class="wp-block-heading">The Real Problem: Outdated Systems, Not Fraud</h2>
Experts say Musk likely misinterpreted a database called Numident, ABC News reported, which contains records of every person assigned a Social Security number. Many older entries lack death dates because they were created before digital record-keeping. A 2023 audit found nearly 19 million such cases, but the government chose not to fix them due to high costs and minimal impact.
The Social Security Administration also has safeguards in place. Payments automatically stop at age 115, and recipients are periodically checked through Medicare use to confirm they're still alive.
Read Next:
<ul>
<li>Many don&#8217;t know there are tax benefits when buying a unit as an investment —<a href="https://www.benzinga.com/money/casa-shares"> Here&#8217;s how to invest in real estate by mirroring BlackRock's big move</a></li>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.26/share with a $1000 minimum.</a></li>
</ul>

Joe Rogan Fact Checks And Debunks His 'Favorite Billionaire' Elon Musk's Social Security Claims: 'This Isn't A Vampire Conspiracy'

Scotiabank analyst John Zamparo downgrades George Weston (TSX:<a class="ticker" href="https://www.benzinga.com/stock/WN#TSX">WN</a>) from Sector Outperform to Sector Perform and raises the price target from C$240 to C$241.

Downgrades

TSX:WN

Scotiabank Downgrades George Weston to Sector Perform, Raises Price Target to C$241

Intuitive Machines Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNR#NASDAQ">LUNR</a>) has achieved a milestone in lunar exploration with the successful <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g44004855/intuitive-machines-im-2-lunar-lander-successfully-commissioned-and-en-route-to-the-moon" rel="noreferrer noopener">launch of its IM-2 mission.</a>
The company&#8217;s Athena lunar lander, part of the Nova-C class, was carried into space by SpaceX&#8217;s Falcon 9 rocket, departing from NASA&#8217;s Kennedy Space Center in Florida.
This historic mission is the first to send three lunar landers to the Moon at the same time.
Following its launch, the Athena lander successfully stabilized its orientation and began solar charging. The spacecraft also established reliable radio communication with Intuitive&#8217;s mission operations center in Houston.
&#8220;Athena joining a historic wave of lunar landers on their way to the Moon is an extraordinary moment,&#8221; said Intuitive Machines CEO Steve Altemus.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/25/02/44005238/norwegian-cruise-line-sails-past-q4-expectations-eps-soars-margins-expand-and-demand-stays-hot" rel="noreferrer noopener">Norwegian Cruise Line Sails Past Q4 Expectations: EPS Soars, Margins Expand And Demand Stays Hot</a>
&#8220;While the most vital part of this mission lies ahead, we believe this is a signal that lunar services are rapidly advancing alongside civil and commercial intent to establish a foothold on the Moon to reach further into the Solar System.&#8221;
Athena is now getting ready for a series of important engine burns to adjust its trajectory in preparation for lunar orbit insertion, slated for March 3, 2025. Intuitive Machines is targeting a lunar landing on March 6, 2025.
Launched from NASA&#8217;s Kennedy Space Center&#8217;s Launch Complex 39A at 7:16 p.m. ET, Athena achieved its intended orbit approximately 44 minutes after liftoff, establishing initial contact with mission control at 8:17 p.m. ET.
The IM-2 mission represents Intuitive Machines&#8217; second lunar exploration mission, playing a key role in NASA&#8217;s Commercial Lunar Payload Services (CLPS) initiative as part of the Artemis program.
As a key component of the CLPS initiative, Athena will conduct vital scientific and technological tests designed to pave the way for future human missions to the Moon.
Price Action: LUNR shares are trading lower by 6.61% at $15.41 at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/25/02/43980853/why-is-mullen-automotive-stock-skyrocketing-today" target="_blank" rel="noreferrer noopener">Mullen EVs Receives Approval For Government And Educational Purchases</a></li>
</ul>
Image via Shutterstock.

LUNR

SpaceX Rocket Launches Intuitive Machines' Athena Lander: Details

JPMorgan analyst Christopher Horvers reiterated the Neutral rating on Advance Auto Parts Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AAP#NYSE">AAP</a>), with a price forecast of $41.
Yesterday, the company reported fourth-quarter adjusted earnings per share of $1.18 loss, which is in line<a target="_blank" href="https://www.benzinga.com/news/earnings/25/02/43973611/advance-auto-parts-q4-sales-beat-expectations-but-margins-slide-stock-dips" rel="noreferrer noopener">&nbsp;with the analyst consensus estimate</a>. Quarterly sales of $2 billion (down 0.9% year over year) outpaced the street view of $1.93 billion. Comparable store sales for the fourth quarter decreased 1.0%.
The analyst maintains a Neutral rating, noting Advance Auto Parts is losing market share, reversing course on pricing, and expecting a margin below 1% in 2024, much lower than its prior long-term target.
The analyst seeks more clarity due to Advance Auto Parts&#8217; ongoing turnaround.
Horvers highlights that Advance Auto Parts anticipates modest macro improvement in the second half of the year.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/25/02/44015322/nvidia-analyst-sees-significant-upside-for-stock-with-favorable-riskreward" rel="noreferrer noopener">Nvidia Analyst Sees &#8216;Significant Upside&#8217; For Stock With Favorable Risk/Reward</a>
The analyst notes that Advance Auto Parts sees strength in filters, fluids, and chemicals, but continued weakness in discretionary categories, which is not expected to improve in FY25.
The slower start to first quarter was attributed to weather, tax refunds, and general softness in its core consumer.
However, management expects seasonal comparisons to ease in the coming weeks and is preparing for when the weather improves.
Horvers now models first quarter and FY25 comps at -2% and +0.6%, respectively.
Horvers highlights that the company expects to achieve a mid-40s GM and a 7% operating margin by 2027, with a strong 2025 gross margin exit rate in Q4.
The analyst models a first-quarter gross margin of 43.8% and a 2025 gross margin of 44.0%.
Price Action: AAP shares are trading higher by 1.41% to $38.25&nbsp;at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/management/24/10/41294313/does-jensen-huang-check-nvidia-stock-price-daily" target="_blank" rel="noreferrer noopener">Does Jensen Huang Check Nvidia Stock Price Daily?</a></li>
</ul>
Image: Shutterstock

Markets

Is Advance Auto Parts Turning The Corner? Analyst Predicts Slow Recovery And Market Share Losses

Scotiabank analyst Allan Verkhovski maintains Workday (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDAY#NASDAQ">WDAY</a>) with a Sector Outperform and raises the price target from $340 to $355.

WDAY

Scotiabank Maintains Sector Outperform on Workday, Raises Price Target to $355

Macro Economic Events

Global

Economics

Canada PM Trudeau Says 'We Will Have An Immediate And Extremely Strong Response' If U.S. Imposes Tariffs Next Tuesday

Scotiabank analyst Andres Coello maintains Telefonica Brasil (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VIV#NYSE">VIV</a>) with a Sector Perform and lowers the price target from $10.4 to $9.2.

Scotiabank Maintains Sector Perform on Telefonica Brasil, Lowers Price Target to $9.2

J.P. Morgan analyst Ken Goldman reiterated an <a href="https://www.benzinga.com/quote/BYND/analyst-ratings">Underweight rating</a> on the shares of Beyond Meat Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BYND#NASDAQ">BYND</a>).
In the fourth-quarter, the El Segundo, California-based company exceeded revenue expectations by $1.1 million, although EBITDA fell short of consensus Metrix estimates by $7 million, primarily due to a weaker-than-anticipated gross margin, said the analyst.
The 2025 revenue guidance also underperformed, with the midpoint forecast of approximately $327 million, below the Consensus Metrix estimate of $337 million. 
The company projects a gross margin of around 20% for 2025, close to the Street&#8217;s expectation of 20.5%. On the operating expenses front, Beyond Meat continues to make progress by announcing additional savings. But the midpoint guidance of $170 million is slightly below the Street's $173 million estimate, Goldman says.
Beyond said its operating expenses would be reduced by $5.5 million to $6.5 million&nbsp;after its plan to cut 44 positions in North America and the EU.
Also Read: <a href="https://www.benzinga.com/news/earnings/25/02/44005238/norwegian-cruise-line-sails-past-q4-expectations-eps-soars-margins-expand-and-demand-stays-hot">Norwegian Cruise Line Sails Past Q4 Expectations: EPS Soars, Margins Expand And Demand Stays Hot</a>
Overall, the analyst does not see significant changes to the consensus EBITDA for 2025, though the revenue outlook is expected to align with the company's guidance.
While revenue is expected to grow (+MSD%) in 2H24, it&#8217;s important to note that BYND has a history of missing its guidance.
Over the past five years, the company's sales or gross margin projections have consistently fallen short of initial forecasts. Therefore, investors should be cautious about expecting significant upside from the 2025 guidance provided today, the analyst asserted.
The analyst changes the 2025 EBITDA estimate from -$63 million to -$61 million and for 2026, the estimate is changed from -$44 million to -$39 million.
While demand for its products may improve long-term and the company is well-positioned in the alt-meat market, the analyst thinks the path to profitability remains uncertain, and current demand patterns are flat. 
Price Action: BYND shares are trading lower by 9.41% at $3.23 at last check Thursday.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/25/02/43980853/why-is-mullen-automotive-stock-skyrocketing-today">Mullen EVs Receives Approval For Government And Educational Purchases</a></li>
</ul>
Image: Shutterstock

BYND

Beyond Meat Faces Flat Demand In 2025, Path To Profitability Remains Uncertain: Analyst

Scotiabank analyst Allan Verkhovski maintains Sprout Social (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPT#NASDAQ">SPT</a>) with a Sector Perform and lowers the price target from $28 to $25.

Scotiabank Maintains Sector Perform on Sprout Social, Lowers Price Target to $25

Scotiabank analyst Ovais Habib maintains Skeena Resources (TSX:<a class="ticker" href="https://www.benzinga.com/stock/SKE#TSX">SKE</a>) with a Sector Outperform and raises the price target from C$14 to C$14.5.

TSX:SKE

Scotiabank Maintains Sector Outperform on Skeena Resources, Raises Price Target to C$14.5

<a href="https://www.bloomberg.com/news/articles/2025-02-27/meta-in-talks-to-raise-35-billion-for-data-center-financing-led-by-apollo?utm_content=business&amp;utm_medium=social&amp;utm_source=twitter&amp;cmpid=socialflow-twitter-business&amp;utm_campaign=socialflow-organic&amp;sref=ZoyErlU1" title="https://www.bloomberg.com/news/articles/2025-02-27/meta-in-talks-to-raise-35-billion-for-data-center-financing-led-by-apollo?utm_content=business&amp;utm_medium=social&amp;utm_source=twitter&amp;cmpid=socialflow-twitter-business&amp;utm_campaign=socialflow-organic&amp;sref=ZoyErlU1">https://www.bloomberg.com/news/articles/2025-02-27/meta-in-talks-to-raise-35-billion-for-data-center-financing-led-by-apollo?utm_content=business&amp;utm_medium=social&amp;utm_source=twitter&amp;cmpid=socialflow-twitter-business&amp;utm_campaign=socialflow-organic&amp;sref=ZoyErlU1</a>

Financing

'Meta In Talks To Raise $35B For Data-Center Financing Led By Apollo' - Bloomberg News

Federal Reserve

Fed's Hammack Says Good Reasons To Expect Inflation To Come Down Further; Further Easing In Inflation Far From Certain, Upside Risks 'Abound'; Easing Inflation Has Been Uneven And Has Slowed; Equity Market Valuations Are High Right Now; Over Longer Run, Economy Can Adapt To Higher Interest Rates

Press Releases

Cogent Biosciences Announces Bezuclastinib Presentations at the 66th Annual American Society of Hematology (ASH) Meeting

Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2024 Financial Results

Cogent Biosciences Announces Positive Updated Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)

Cogent Biosciences Announces Updated Clinical Results from SUMMIT, Showcasing Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients

Cogent Biosciences Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference

Cogent Biosciences Announces Planned 2025 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Therapeutics

Cogent Biosciences to Participate in the Guggenheim Biotech Conference

Cogent Biosciences Announces Bezuclastinib Poster in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2025 AAAAI Annual Meeting

Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results

Cogent Biosciences Announces SUMMIT Continues to Showcase Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients

Comments

Cogent Biosciences

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL